Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more

Recent & Breaking News (NDAQ:MRNS)

Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock

Business Wire December 8, 2020

Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock

Business Wire December 7, 2020

Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update

Business Wire December 7, 2020

Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder

Business Wire December 7, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 4, 2020

Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020

Business Wire December 2, 2020

Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting

Business Wire November 23, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 10, 2020

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

Business Wire November 9, 2020

Marinus Pharmaceuticals Appoints Christy Shafer as Chief Commercial Officer

Business Wire November 9, 2020

Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020

Business Wire October 20, 2020

Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences

Business Wire October 19, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 14, 2020

Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)

Business Wire September 24, 2020

Marinus Announces One-for-Four Reverse Stock Split

Business Wire September 22, 2020

Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy

Business Wire September 14, 2020

Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure

Business Wire September 14, 2020

Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

Business Wire September 8, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 11, 2020

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Business Wire August 6, 2020